$OCS News
Last published 2d ago
- 2d agoOCSGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - OCULIS HOLDING AGEarnings Call TranscriptsAll right, good afternoon. Welcome to Guggenheim's third annual healthcare innovation conference. My name is Yatin Suneja, I'm one of the biotech analysts here at the firm. Our next presenting company is Oculus Holding.
- 2d agoOCSOculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development PipelineGlobeNewswireZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today
- 2d agoOCSOculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development PipelineGlobeNewswireZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough...
- 2d agoOCSOculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development PipelineGlobeNewswireZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough...
- 1w agoOCSOculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline CatalystsGlobeNewswireLicaminlimab (PREDICT-1): Patient randomization is now complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease (DED). Topline results are anticipated around year-end
- 1w agoOCSOculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology InnovationGlobeNewswireBjörn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications
- 1w agoOCSOculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS SummitGlobeNewswireZUG, Switzerland, October 29th, 2026 -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in
- 2w agoOCSOculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic NeuritisGlobeNewswirePrivosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological
- 3w agoOCSOculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS MeetingGlobeNewswirePresentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (NASDAQ:OCS)
- 3w agoOCSOculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye DiseaseGlobeNewswireHigh-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large
- 1mo agoOCSOculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty DayGlobeNewswireLicaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 --
- 1mo agoOCSBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - OCULIS HOLDING AGEarnings Call TranscriptsGreat. Thank you all for taking the time to join us for another session at the Baird Healthcare Conference. For those unfamiliar, my name is Jack Allen, and I cover the biotech space. And for this session, we're joined b
- 2mo agoOCSFirst Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic NeuritisGlobeNewswireZUG, Switzerland, August 24th, 2026 -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in
- 3mo agoOCSOculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology CompanyGlobeNewswireTransaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at closing and up to
- 3mo agoOCSOculis Reports Q2 2026 Financial Results and Provides Company UpdateGlobeNewswireCompany pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS) relapses following
- 3mo agoOCSOculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis RelapsesGlobeNewswireThe FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical need The FDA confirmed that
- 4mo agoOCSOculis to Participate at the Piper Sandler Virtual Ophthalmology ConferenceGlobeNewswireZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing
- 5mo agoOCSOculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026GlobeNewswireZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on breakthrough innovations to address significant
- 5mo agoOCSOculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye DiseaseGlobeNewswirePREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DEDThis FDA-aligned trial targets the specific TNFR1
- 5mo agoOCSOculis to Present at the 47th Annual Goldman Sachs Global Healthcare ConferenceGlobeNewswireZUG, Switzerland, June 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and
- 5mo agoOCSOculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular EdemaGlobeNewswireThe primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial and persistent
- 6mo agoOCSOculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of DirectorsGlobeNewswireZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug,
- 6mo agoOCSOculis Reports Q1 2026 Financial Results and Provides Company UpdateGlobeNewswirePipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase,
- 6mo agoOCSOculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational TrialGlobeNewswireSpecial Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON)FDA Breakthrough Therapy and EMA PRIME designations in ON
- 6mo agoOCSLatest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual MeetingGlobeNewswireKey findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) managementOculis is on track to report topline results in June
- 6mo agoOCSOculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingGlobeNewswireLatest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D.New
- 6mo agoOCSOculis Publishes Invitation to the Annual General MeetingGlobeNewswireZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at
- 6mo agoOCSOculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular EdemaGlobeNewswireLast patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A non-invasive topical treatment for diabetic macular edema (DME) has the potential
- 7mo agoOCSOculis to Participate in Upcoming Investor ConferencesGlobeNewswireZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and
- 7mo agoOCSOculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic NeuritisGlobeNewswirePRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative long-term visual
- 8mo agoOCSOculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual MeetingGlobeNewswireZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (NASDAQ:OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and
- 8mo agoOCSOculis to Participate in Upcoming Investor ConferencesGlobeNewswireZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and
- 8mo agoOCSOculis Reports Q4 and Full Year 2025 Financial Results and Provides Company UpdateGlobeNewswireSignificant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic
- 8mo agoOCSOculis Appoints Katie Kazem as Chief Legal OfficerGlobeNewswireMs. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO)
- 10mo agoOCSOculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare ConferenceGlobeNewswireBreakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. aloneMultiple milestones anticipated from late-stage
- 1y agoOCSOculis Reports Q3 2025 Financial Results and Provides Company UpdateGlobeNewswireOculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) following positive FDA
- 1y agoOCSOculis to Participate in Upcoming November Investor ConferencesGlobeNewswireZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in
- 1y agoOCSOculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor DevelopmentGlobeNewswireZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on breakthrough innovations to address significant
- 1y agoOCSOculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025GlobeNewswireZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with
- 1y agoOCSOculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective TherapyGlobeNewswireSuccessful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER
- 1y agoOCSOculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMSGlobeNewswireZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant
- 1y agoOCSOculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025GlobeNewswireZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant
- 1y agoOCSOculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology ConferencesGlobeNewswirePhase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in
- 1y agoOCSOculis to Participate in Upcoming September Investor ConferencesGlobeNewswireZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases
- 1y agoOCSOculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical AdvisorsGlobeNewswireMark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in
- 1y agoOCSOculis Reports Q2 2025 Financial Results and Provides Company UpdateGlobeNewswireFocused execution in Q2 2025 to advance Oculis' pipeline in ophthalmology and neuro-ophthalmologyOCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with topline results expected in Q2 2026 for the first
- 1y agoOCSOculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceGlobeNewswireZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions
- 1y agoOCSOculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual ConferenceGlobeNewswireZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions
- 1y agoOCSOculis Upsized Loan Facility to Access up to CHF 100 millionGlobeNewswireZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and
- 1y agoOCSOculis Publishes Results of 2025 Annual General MeetingGlobeNewswireZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug,